[Guihuang Formula for type III prostatitis with damp-heat stasis syndrome in the essence chamber: A clinical trial]

To investigate the efficacy and safety of Guihuang Formula (GHF) in the treatment of type III prostatitis with the syndrome of damp-heat stasis in the essence chamber.

This study included 120 cases of type III prostatitis with damp-heat stasis syndrome in the essence chamber, which were randomly and equally divided into a GHF and a control group, the former treated with GHF and the latter with Tamsulosin Hydrochloride Sustained-Release Capsules, both for 6 successive weeks. We followed up the patients for 4 weeks, recorded the NIH-CPSI, TCM symptom scores, and results of prostatic fluid routine, blood and urine routine, liver and kidney function and electrocardiogram examinations, and compared them between the two groups of patients before and after treatment.

Compared with the baseline, the total NIH-CPSI scores were significantly decreased in both the GHF and control groups after 6 weeks of treatment, even more significantly in the former group (28.34±9.23 vs 6.78±3.53, P<0.05) than in the latter (27.81±8.28 vs 14.48±4.27, P<0.05), so were the scores on pain, voiding symptoms, quality of life (QOL) impact, TCM symptoms and WBC count (all P<0.05), while the number of lecithin bodies remarkably increased (P<0.05). There were statically significant differences in the above parameters at 4, 6 and 10 weeks of medication (P<0.05), but not at 2 weeks (P>0.05). No obvious abnormalities or adverse reactions were observed in either of the two groups during the treatment.

Guihuang Formula is safe and effective in the treatment of type III prostatitis with the syndrome of damp-heat stasis in the essence chamber.